BACKGROUND: Intensive lifestyle interventions (ILIs) are the first-line approach to effectively treat obesity and manage associated cardiometabolic risk factors. Because few people have access to ILIs in academic health centers, primary care must implement similar approaches for a meaningful effect on obesity and cardiometabolic disease prevalence. To date, however, effective lifestyle-based obesity treatment in primary care is limited. We examined the effectiveness of a pragmatic ILI for weight loss delivered in primary care among a racially diverse, low-income population with obesity for improving cardiometabolic risk factors over 24 months. METHODS: The PROPEL trial (Promoting Successful Weight Loss in Primary Care in Louisiana) randomly allocated 18 clinics equally to usual care or an ILI and subsequently enrolled 803 (351 usual care, 452 ILI) adults (67% Black, 84% female) with obesity from participating clinics. The usual care group continued to receive their normal primary care. The ILI group received a 24-month high-intensity lifestyle-based obesity treatment program, embedded in the clinic setting and delivered by health coaches in weekly sessions initially and monthly sessions in months 7 through 24. RESULTS: As recently demonstrated, participants receiving the PROPEL ILI lost significantly more weight over 24 months than those receiving usual care (mean difference, -4.51% [95% CI, -5.93 to -3.10]; P<0.01). Fasting glucose decreased more in the ILI group compared with the usual care group at 12 months (mean difference, -7.1 mg/dL [95% CI, -12.0 to -2.1]; P<0.01) but not 24 months (mean difference, -0.8 mg/dL [95% CI, -6.2 to 4.6]; P=0.76). Increases in high-density lipoprotein cholesterol were greater in the ILI than in the usual care group at both time points (mean difference at 24 months, 4.6 mg/dL [95% CI, 2.9-6.3]; P<0.01). Total:high-density lipoprotein cholesterol ratio and metabolic syndrome severity (z score) decreased more in the ILI group than in the usual care group at both time points, with significant mean differences of the change of -0.31 (95% CI, -0.47 to -0.14; P<0.01) and -0.21 (95% CI, -0.36 to -0.06; P=0.01) at 24 months, respectively. Changes in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and blood pressure did not differ significantly between groups at any time point. CONCLUSIONS: A pragmatic ILI consistent with national guidelines and delivered by trained health coaches in primary care produced clinically relevant improvements in cardiometabolic health in an underserved population over 24 months. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02561221.
BACKGROUND: Intensive lifestyle interventions (ILIs) are the first-line approach to effectively treat obesity and manage associated cardiometabolic risk factors. Because few people have access to ILIs in academic health centers, primary care must implement similar approaches for a meaningful effect on obesity and cardiometabolic disease prevalence. To date, however, effective lifestyle-based obesity treatment in primary care is limited. We examined the effectiveness of a pragmatic ILI for weight loss delivered in primary care among a racially diverse, low-income population with obesity for improving cardiometabolic risk factors over 24 months. METHODS: The PROPEL trial (Promoting Successful Weight Loss in Primary Care in Louisiana) randomly allocated 18 clinics equally to usual care or an ILI and subsequently enrolled 803 (351 usual care, 452 ILI) adults (67% Black, 84% female) with obesity from participating clinics. The usual care group continued to receive their normal primary care. The ILI group received a 24-month high-intensity lifestyle-based obesity treatment program, embedded in the clinic setting and delivered by health coaches in weekly sessions initially and monthly sessions in months 7 through 24. RESULTS: As recently demonstrated, participants receiving the PROPEL ILI lost significantly more weight over 24 months than those receiving usual care (mean difference, -4.51% [95% CI, -5.93 to -3.10]; P<0.01). Fasting glucose decreased more in the ILI group compared with the usual care group at 12 months (mean difference, -7.1 mg/dL [95% CI, -12.0 to -2.1]; P<0.01) but not 24 months (mean difference, -0.8 mg/dL [95% CI, -6.2 to 4.6]; P=0.76). Increases in high-density lipoprotein cholesterol were greater in the ILI than in the usual care group at both time points (mean difference at 24 months, 4.6 mg/dL [95% CI, 2.9-6.3]; P<0.01). Total:high-density lipoprotein cholesterol ratio and metabolic syndrome severity (z score) decreased more in the ILI group than in the usual care group at both time points, with significant mean differences of the change of -0.31 (95% CI, -0.47 to -0.14; P<0.01) and -0.21 (95% CI, -0.36 to -0.06; P=0.01) at 24 months, respectively. Changes in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and blood pressure did not differ significantly between groups at any time point. CONCLUSIONS: A pragmatic ILI consistent with national guidelines and delivered by trained health coaches in primary care produced clinically relevant improvements in cardiometabolic health in an underserved population over 24 months. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02561221.
Entities:
Keywords:
cardiovascular diseases; life style; obesity; primary health care
Authors: Sherry L Pagoto; Kristin L Schneider; Jessica L Oleski; Juliana M Luciani; Jamie S Bodenlos; Matt C Whited Journal: Obesity (Silver Spring) Date: 2011-06-02 Impact factor: 5.002
Authors: Michael D Jensen; Donna H Ryan; Caroline M Apovian; Jamy D Ard; Anthony G Comuzzie; Karen A Donato; Frank B Hu; Van S Hubbard; John M Jakicic; Robert F Kushner; Catherine M Loria; Barbara E Millen; Cathy A Nonas; F Xavier Pi-Sunyer; June Stevens; Victor J Stevens; Thomas A Wadden; Bruce M Wolfe; Susan Z Yanovski; Harmon S Jordan; Karima A Kendall; Linda J Lux; Roycelynn Mentor-Marcel; Laura C Morgan; Michael G Trisolini; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: T J Orchard; M Temprosa; E Barrett-Connor; S E Fowler; R B Goldberg; K J Mather; S M Marcovina; M Montez; R E Ratner; C D Saudek; H Sherif; K E Watson Journal: Diabet Med Date: 2013-01 Impact factor: 4.359
Authors: Xavier Pi-Sunyer; George Blackburn; Frederick L Brancati; George A Bray; Renee Bright; Jeanne M Clark; Jeffrey M Curtis; Mark A Espeland; John P Foreyt; Kathryn Graves; Steven M Haffner; Barbara Harrison; James O Hill; Edward S Horton; John Jakicic; Robert W Jeffery; Karen C Johnson; Steven Kahn; David E Kelley; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Brenda Montgomery; David M Nathan; Jennifer Patricio; Anne Peters; J Bruce Redmon; Rebecca S Reeves; Donna H Ryan; Monika Safford; Brent Van Dorsten; Thomas A Wadden; Lynne Wagenknecht; Jacqueline Wesche-Thobaben; Rena R Wing; Susan Z Yanovski Journal: Diabetes Care Date: 2007-03-15 Impact factor: 19.112
Authors: Fabian J Brunner; Christoph Waldeyer; Francisco Ojeda; Veikko Salomaa; Frank Kee; Susana Sans; Barbara Thorand; Simona Giampaoli; Paolo Brambilla; Hugh Tunstall-Pedoe; Marie Moitry; Licia Iacoviello; Giovanni Veronesi; Guido Grassi; Ellisiv B Mathiesen; Stefan Söderberg; Allan Linneberg; Hermann Brenner; Philippe Amouyel; Jean Ferrières; Abdonas Tamosiunas; Yuriy P Nikitin; Wojciech Drygas; Olle Melander; Karl-Heinz Jöckel; David M Leistner; Jonathan E Shaw; Demosthenes B Panagiotakos; Leon A Simons; Maryam Kavousi; Ramachandran S Vasan; Robin P F Dullaart; S Goya Wannamethee; Ulf Risérus; Steven Shea; James A de Lemos; Torbjørn Omland; Kari Kuulasmaa; Ulf Landmesser; Stefan Blankenberg Journal: Lancet Date: 2019-12-03 Impact factor: 79.321
Authors: Raymond Carvajal; Thomas A Wadden; Adam G Tsai; Katherine Peck; Caroline H Moran Journal: Ann N Y Acad Sci Date: 2013-01-16 Impact factor: 5.691
Authors: Kershaw V Patel; Matthew W Segar; Carl J Lavie; Nitin Kondamudi; Ian J Neeland; Jaime P Almandoz; Corby K Martin; Salvatore Carbone; Javed Butler; Tiffany M Powell-Wiley; Ambarish Pandey Journal: Circulation Date: 2021-12-03 Impact factor: 29.690
Authors: James L Dorling; Corby K Martin; Qingzhao Yu; Wentao Cao; Christoph Höchsmann; John W Apolzan; Robert L Newton; Kara D Denstel; Emily F Mire; Peter T Katzmarzyk Journal: Am J Clin Nutr Date: 2022-10-06 Impact factor: 8.472
Authors: Peter T Katzmarzyk; Kara D Denstel; Corby K Martin; Robert L Newton; John W Apolzan; Emily F Mire; Ronald Horswell; William D Johnson; Andrew W Brown; Dachuan Zhang Journal: Clin Obes Date: 2022-04-12
Authors: Julia Simões Corrêa Galendi; Renata Giacomini Occhiuto Ferreira Leite; Luísa Rocco Banzato; Vania Dos Santos Nunes-Nogueira Journal: Int J Environ Res Public Health Date: 2022-04-02 Impact factor: 3.390
Authors: Tamar S Polonsky; Amit Khera; Michael D Miedema; Douglas D Schocken; Peter W F Wilson Journal: J Am Heart Assoc Date: 2022-07-04 Impact factor: 6.106
Authors: Ruixin Zhu; Ionut Craciun; Jan Bernhards-Werge; Elli Jalo; Sally D Poppitt; Marta P Silvestre; Maija Huttunen-Lenz; Melitta A McNarry; Gareth Stratton; Svetoslav Handjiev; Teodora Handjieva-Darlenska; Santiago Navas-Carretero; Jouko Sundvall; Tanja C Adam; Mathijs Drummen; Elizabeth J Simpson; Ian A Macdonald; Jennie Brand-Miller; Roslyn Muirhead; Tony Lam; Pia S Vestentoft; Kristine Færch; J Alfredo Martinez; Mikael Fogelholm; Anne Raben Journal: Diabetologia Date: 2022-05-25 Impact factor: 10.460